Pharmacists and pharmacy staff faced extraordinary pressure during the COVID pandemic, with some losing their lives, highlighting the importance of ensuring workplace safety and mental health support.
The expansion of scope for pharmacists during COVID has highlighted the potential for community pharmacists to deliver further professional services, adding value to the pharmacy space.
With this in mind, as well as pharmacy development goals aligned with the UN’s Sustainable Development Goals, there has now been change in the global federation representing 4 million pharmacists across over 100 countries, with the election and appointment of an Australian pharmacist as President.
In late 2023, Paul Sinclair, was elected as the President of the International Pharmaceutical Federation (FIP), the first Australian to hold the position. In accordance with the FIP Statutes, president-elect Paul Sinclair has commenced performing the duties of president following the unexpected passing of his predecessor Dominique Jordan in Switzerland.
Mr Sinclair, a community pharmacist and former community pharmacy proprietor, has served on FIP for a number of years, including as president of its Community Pharmacy Section (2014–18) and chair of FIP’s Board of Pharmaceutical Practice since 2018.
Paul Sinclair’s extensive experience in the pharmaceutical industry, including his roles as President of the International Pharmaceutical Federation and chair of the Australian Association of Consultant Pharmacists, highlights his deep knowledge and expertise in the field.
His appointment will be ratified at the 81ST FIP World Congress of Pharmacy and Pharmaceutical Sciences being held in Brisbane, Australia from 24 to 28 September 2023.
The Congress theme is “Pharmacy building a sustainable future for healthcare – Aligning goals to 2030”. Paul spoke with Mike Lesner, host of Global Health Talks on the themes for the Congress, the reach of the Federation and the common and unique challenges facing the pharmacy industry across the globe.
About the International Pharmaceutical Federation (FIP)
The International Pharmaceutical Federation (FIP) is the global body for pharmacy, pharmaceutical sciences and pharmaceutical education. Through 152 national organisations, academic institutional members and individual members, FIP represents over four million pharmacists, pharmaceutical scientists and pharmaceutical educators around the world.
Founded in 1912, FIP is a non-governmental organisation with its head office in the Netherlands. Through partnerships and extensive pharmacy and pharmaceutical sciences network, FIP works to support the development of the pharmacy profession, through practice and emerging scientific innovations, and through developing the pharmacy workforce in order to meet the world’s health care needs and expectations.
You Might also like
-
Preventing surgery related infections
Surgical site infections (SSI) is infection that occurs after surgery in a part of the body where the surgery took place. Surgical site infections are seen as the most common healthcare-associated infection, significantly impacting healthcare resources in the UK and across the World.
Professor Leaper speaks on needing ongoing good antibiotic stewardship to reduce the risk of antibiotic-resistant and emergent organisms. The pressures on administering antibiotics have led to tighter management and stewardship of antibiotics.
-
Global effort to reduce postoperative infection risk
Infection rates following surgical procedure vary across countries, however the causes and the ranges of variation are not well understood.
The causes of the infections are not as high as would be assumed on the surgical procedure, but co-morbidity and lifestyle choices including alcohol consumption may exacerbate risk. As Dr Edmiston states, there are a myriad of causes, and funding is limited in many countries. However there are some solutions, where goals, performance tracking against the goals and better communication is needed.
-
Australia’s digital health push into new national markets
Infection rates following surgical procedure vary across countries, however the causes and the ranges of variation are not well understood.
The causes of the infections are not as high as would be assumed on the surgical procedure, but co-morbidity and lifestyle choices including alcohol consumption may exacerbate risk. As Dr Edmiston states, there are a myriad of causes, and funding is limited in many countries. However there are some solutions, where goals, performance tracking against the goals and better communication is needed.